Category Press Releases

NationsBenefits® Partners with TS Emporium to Expand Access to Culturally Relevant Health Products

NationsBenefits® Partners with TS Emporium to Expand Access to Culturally Relevant Health Products

NationsBenefits® Partners with TS Emporium to Expand Access to Culturally Relevant Health Products NationsBenefits®, a leading provider of supplemental benefits and healthcare fintech solutions, has announced a strategic partnership with TS Emporium, a well-established provider of Asian-focused food, wellness, and…

Read MoreNationsBenefits® Partners with TS Emporium to Expand Access to Culturally Relevant Health Products
UroGen Pharma Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

UroGen Pharma Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

UroGen Pharma Reports Inducement Grants Under Nasdaq Rule 5635(c)(4) UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotechnology company focused on developing and commercializing innovative therapies for urothelial and specialty cancers, has announced the issuance of inducement restricted stock units (“RSUs”)…

Read MoreUroGen Pharma Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
ENCell’s EN001 Granted FDA Orphan Drug Status for Charcot-Marie-Tooth Disease

ENCell’s EN001 Granted FDA Orphan Drug Status for Charcot-Marie-Tooth Disease

ENCell’s EN001 Granted FDA Orphan Drug Designation for Charcot-Marie-Tooth Disease ENCell, a pioneering biopharmaceutical company specializing in cell and gene therapy CDMO and novel drug development, announced that its investigational drug EN001 has received Orphan Drug Designation (ODD) from the…

Read MoreENCell’s EN001 Granted FDA Orphan Drug Status for Charcot-Marie-Tooth Disease
Ventus Therapeutics Showcases Caspase-45 as Key Therapeutic Targets in Nature Reviews Immunology

Ventus Therapeutics Showcases Caspase-4/5 as Key Therapeutic Targets in Nature Reviews Immunology

Ventus Therapeutics Showcases Caspase-4/5 as Key Therapeutic Targets in Nature Reviews Immunology Ventus Therapeutics, a clinical-stage biopharmaceutical company focused on advancing innovative small-molecule therapies for immunological, inflammatory, and neurological disorders, has announced a significant publication in the prestigious peer-reviewed journal…

Read MoreVentus Therapeutics Showcases Caspase-4/5 as Key Therapeutic Targets in Nature Reviews Immunology
Orbital Therapeutics Welcomes Biopharma Leader Geno Germano to Board of Directors

Orbital Therapeutics Welcomes Biopharma Leader Geno Germano to Board of Directors

Orbital Therapeutics Strengthens Leadership with the Appointment of Biopharma Veteran Geno Germano to Its Board of Directors Orbital Therapeutics, a pioneering biotechnology company focused on advancing RNA-based medicines to address a wide range of diseases, has announced the appointment of…

Read MoreOrbital Therapeutics Welcomes Biopharma Leader Geno Germano to Board of Directors
CB Capital Gives Estrella Immunopharma (ESLA) Buy Rating, $14 Target

CB Capital Gives Estrella Immunopharma (ESLA) Buy Rating, $14 Target

Estrella Immunopharma Receives Buy Rating from CB Capital Partners with a $14.00 Price Target Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company pioneering the development of CD19 and CD22-targeted ARTEMIS® T-cell therapies for cancer and…

Read MoreCB Capital Gives Estrella Immunopharma (ESLA) Buy Rating, $14 Target